TY - JOUR
T1 - High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients
T2 - Treatment technique and related complications
AU - Bradley, Jeffrey
AU - Reft, Chester
AU - Goldman, Stewart
AU - Rubin, Charles
AU - Nachman, James
AU - Larson, Richard
AU - Hallahan, Dennis E.
N1 - Funding Information:
Bone marrow transplantation (BMT) is used in the treatment of patients with relapsed or refractory hematolgic malignancies including acute lymphoblastic leukemia (ALL), acute myelocytic leukemia (AML), and chronic lymphocytic leukemia (CML). Myeloablative therapy followed by donor stem cell reinfusion has resulted in cures in approximately one-half to one-third of patients (1, 4, 6, 8, IO, 24-26). Effective preparatory regimens include total-body irradiation (TBI) combined with high-dose cyclophosphamide and/or high-dose etoposide (2. 3, 5, 12, 13, 16, 18, 22, 23). The major causeso f death for transplant patients Reprint requestst o: Dennis Hallahan. M.D., Departmento f RadiationO ncology, MC 0085.5 841 S. Maryland, University of Chicago,C hicago,I L 606037. AcknnM./edgment.s-This work was supported by NIH Grant CA include relapse, graft-vs.-host disease( GVHD). infections, and treatment related organ injury. Because 2%30% of patients treated with the above regimens die of leukemia relapse, it may be suggested that treatment intensity is inadequate. Improved radiation dosimetry to the patient’s bone marrow may help improve cure rates by reducing organ injury.
PY - 1998/1/15
Y1 - 1998/1/15
N2 - Purpose: Bone marrow transplantation with conditioning regimens that include total-body irradiation (TBI) is widely used in patients with acute lymphoblastic and acute myelocytic leukemias. The major causes of death in this population are relapse of leukemia, infection, and treatment related complications. Our purpose was to achieve a homogenous radiation dose distribution and to minimize the dose to the lungs, liver, and kidneys so that the incidence of organ injury was reduced. Methods and Materials: Dose to the bone marrow, midplane, and periphery was quantified by use of thermoluminescent detectors in a bone-equivalent tissue phantom. In an effort to reduce the risk of complications, we treated relapsed or refractory leukemia patients with TBI administered in fractionated, parallel opposed large fields with 24 MV photons, using tissue compensation and partial- transmission lung shielding. Tissue toxicities were then determined. Results: Dose quantitation in bone-equivalent and tissue-equivalent phantoms demonstrated that backscatter and pair production interactions adjacent to bone increased the bone marrow dose by 6 to 11%. At an SSD of 400 cm and at patient diameters of 20 to 40 cm, the percent inhomogeneity across the phantom with 24 MV photons was 0 to 0.3%, compared to 4 to 6% for 6 MV photons. End-organ toxicities consisted of clinical interstitial pneumonitis in six patients, idiopathic interstitial pneumonitis in three patients, renal toxicity in seven patients, and veno-occlusive disease of the liver in one patient. Toxicities did not correlate with fractionation schedule. Conclusions: Total-body irradiation administered with 24 MV photons increases the dose deposition in bone marrow through pair production and backscatter interactions occurring in bone. Because percent depth dose increases with SSD, the 24 MV beam is more penetrating at a 400 cm distance than at 100 cm and dose homogeneity is improved with higher energies. Thus, the incidence of radiation-mediated injury to lung, liver, and kidney is reduced. This is an effective preparatory regimen for patients with high-risk leukemias requiring bone marrow transplantation.
AB - Purpose: Bone marrow transplantation with conditioning regimens that include total-body irradiation (TBI) is widely used in patients with acute lymphoblastic and acute myelocytic leukemias. The major causes of death in this population are relapse of leukemia, infection, and treatment related complications. Our purpose was to achieve a homogenous radiation dose distribution and to minimize the dose to the lungs, liver, and kidneys so that the incidence of organ injury was reduced. Methods and Materials: Dose to the bone marrow, midplane, and periphery was quantified by use of thermoluminescent detectors in a bone-equivalent tissue phantom. In an effort to reduce the risk of complications, we treated relapsed or refractory leukemia patients with TBI administered in fractionated, parallel opposed large fields with 24 MV photons, using tissue compensation and partial- transmission lung shielding. Tissue toxicities were then determined. Results: Dose quantitation in bone-equivalent and tissue-equivalent phantoms demonstrated that backscatter and pair production interactions adjacent to bone increased the bone marrow dose by 6 to 11%. At an SSD of 400 cm and at patient diameters of 20 to 40 cm, the percent inhomogeneity across the phantom with 24 MV photons was 0 to 0.3%, compared to 4 to 6% for 6 MV photons. End-organ toxicities consisted of clinical interstitial pneumonitis in six patients, idiopathic interstitial pneumonitis in three patients, renal toxicity in seven patients, and veno-occlusive disease of the liver in one patient. Toxicities did not correlate with fractionation schedule. Conclusions: Total-body irradiation administered with 24 MV photons increases the dose deposition in bone marrow through pair production and backscatter interactions occurring in bone. Because percent depth dose increases with SSD, the 24 MV beam is more penetrating at a 400 cm distance than at 100 cm and dose homogeneity is improved with higher energies. Thus, the incidence of radiation-mediated injury to lung, liver, and kidney is reduced. This is an effective preparatory regimen for patients with high-risk leukemias requiring bone marrow transplantation.
KW - Backscatter
KW - High- energy irradiation
KW - Pair production
KW - Thermoluminescent detector (TLD)
KW - Total-body irradiation (TBI)
UR - http://www.scopus.com/inward/record.url?scp=0032518471&partnerID=8YFLogxK
U2 - 10.1016/S0360-3016(97)00578-6
DO - 10.1016/S0360-3016(97)00578-6
M3 - Article
C2 - 9457826
AN - SCOPUS:0032518471
SN - 0360-3016
VL - 40
SP - 391
EP - 396
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 2
ER -